|
|
|
|
| LEADER |
00000nam a2200000 i 4500 |
| 001 |
ELB169542 |
| 003 |
FINmELB |
| 005 |
20220615121057.0 |
| 006 |
m o u |
| 007 |
cr cnu|||||||| |
| 008 |
101124t20112011pauad ob 001 0 eng|d |
| 020 |
|
|
|a 9781451153613
|q (e-book)
|
| 020 |
|
|
|z 9781605473338
|
| 035 |
|
|
|a (OCoLC)755810819
|
| 040 |
|
|
|a FINmELB
|b eng
|e rda
|c FINmELB
|
| 050 |
|
4 |
|a RC271.I45
|b I462 2011
|
| 082 |
0 |
|
|a 616.99/4061
|2 22
|
| 245 |
0 |
0 |
|a Immunomodulating drugs for the treatment of cancer /
|c editor, Asher A.A. Chanan-Khan, MD, Associate Professor of Oncology, Roswell Park Cancer Institute, Buffalo, New York.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Philadelphia :
|b Wolters Kluwer Health/Lippincott Williams & Wilkins,
|c [2011]
|
| 264 |
|
4 |
|c Ã2011
|
| 300 |
|
|
|a 1 online resource (317 pages) :
|b illustrations (some color)
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a computer
|2 rdamedia
|
| 338 |
|
|
|a online resource
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a part I. Introduction -- part II. Preclinical develpment -- part III. Clinical development.
|
| 588 |
|
|
|a Description based on metadata supplied by the publisher and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Santa Fe, Arg.: elibro, 2022. Available via World Wide Web. Access may be limited to eLibro affiliated libraries.
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|
| 650 |
|
0 |
|a Biological response modifiers.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Chanan-Khan, Asher A. A.
|
| 776 |
0 |
8 |
|i Print version:
|t Immunomodulating drugs for the treatment of cancer.
|d Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins, [2011]
|h xiv, 299 pages
|z 9781605473338
|w (DNLM)101548278
|w (DLC)10824454
|
| 797 |
2 |
|
|a elibro, Corp.
|
| 856 |
4 |
0 |
|u https://elibro.uam.elogim.com/ereader/bidiuam/169542
|z Texto completo
|
